Authors
Latest:
The Importance of Precise Reproducibility of AAVsScott Jeffers, PhD, the chief technology officer at GenSight Biologics, discussed using Verdot’s FlexiPro system to produce Lumevoq gene therapy.
Latest:
Ben Creelan, MD, on the Potential of Logic-gated Tmod CAR-T in Lung Cancer and Other Solid TumorsThe medical oncologist at Moffitt Cancer Center spoke about A2 Bio’s A2B530 as part of a larger discussion of novel cell therapy approaches in solid tumors.
Latest:
Evan Zynda, PhD, on Optimizing Manufacturing to Increase Access to Cell TherapyThe senior scientist at Thermo Fisher Scientific discussed the company’s approach to scaling and strategic partnerships.
Latest:
Claire Roddie PhD, FRCPath, MBChB, MRCP, on the Potential Advantage Obe-cel's Fast Off-rate CD19 Binding DomainThe associate professor at University College London also discussed unmet needs that remain in r/r B-ALL and another presentation of interest at ASCO’s 2023 conference.
Latest:
Rajni Agarwal-Hashmi, MD, on Safety Advantages of Gene Therapy in Fanconi Anemia Over SOCThe professor of pediatrics at Stanford Cancer Institute discussed recent data from clinical trials of the lentiviral gene therapy RP-L102.
Latest:
CAR T and Other Emerging Therapies in R/R Multiple Myeloma: Kenneth H. Shain, MD, PhDThe hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.
Latest:
Paula Rodríguez Otero, MD, PhD, on Demonstrating Ide-cel's PFS Superiority in Triple-Class-Exposed R/R Multiple MyelomaThe hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.
Latest:
J. Andrew Livingston, MD, on Starting the Shift Toward Targeted Therapies in SarcomaThe associate professor at MD Anderson Cancer Center discussed his future outlook and goals for the field of sarcoma.
Latest:
Diana Bharucha-Goebel, MD, and Bakri Elsheikh, MBBS, FRCP, on Setting Realistic Goals for Long-Standing SMAThe clinical neurophysiologist at Children’s National and the professor of neurology at The Ohio State University Wexner Medical Center discussed treatment considerations for patients already living with SMA.
Latest:
Dan Shelly, PhD, on Developing an Allogeneic, Adaptable CAR PlatformThe vice president of business development and alliances at Prescient Therapeutics discussed advantages of the OmniCAR, SpyTag, and SpyCatcher technologies.
Latest:
The Power and Potential of Natural Killer Cell Therapies: A New AwakeningNatural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.
Latest:
Targeting Cancers With CAR T and NK CellsJan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s future plans and research.
Latest:
The Potential of ALLO-715 in Relapsed/Refractory Multiple Myeloma: Doris Hansen, MDThe hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.
Latest:
Gene Therapy Well-Tolerated in Late-Onset Pompe DiseaseInterim safety data from the FORTIS study were presented at WORLDSympsoium.
Latest:
Exploring Advanced Approaches for Pain ReliefThe chief executive officer and co-founder of Flexion Therapeutics discussed the company’s pain-focused pipeline, which includes a gene therapy that targets inflammation.
Latest:
Gene Therapy for APOE4 Homozygous Alzheimer DiseaseR. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, discussed Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease.
Latest:
Thomas Povsic, MD, PhD, on Ongoing Research With XC001 Angina Gene TherapyThe interventional cardiologist and professor, Duke University School of Medicine, discussed other populations that may benefit from XC001 and the challenges and opportunities with a surgical delivery of treatment.
Latest:
1-Year Data on Omidubicel Shows Sustained Benefits, Reduced Infection RatesThere was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.
Latest:
The Growing Popularity of Gene Therapy for Retinal DiseasesFoundation Fighting Blindness is helping to support the development of gene therapies for retinal diseases.
Latest:
Advantages of CG0070 Over Standard Care for Non-Muscle Invasive Bladder CancerThe chief executive officer of CG Oncology discussed the role of CG0070 in patients who are unresponsive and responsive to Bacillus Calmette-Guerin immunotherapy.
Latest:
Re-Dosing With Gene Therapies in Rare DiseasesTakashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.
Latest:
The Importance of Collaboration in Developing Next Generation Cell TherapiesDolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies.
Latest:
Gene Therapy for APOE4 Homozygous Alzheimer DiseaseR. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, discussed Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease.
Latest:
Devon J. Shedlock, PhD, on Shifting from Autologous to Allogeneic TherapiesThe chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.
Latest:
Mesenchymal Stem Cells and Other Upcoming Treatments for Progressive MS: Jeffrey Cohen, MDThe director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed upcoming new therapies for relapsing MS.
Latest:
Angela Genge, MD, FRCPC, eMBA, on Targeting STMN2 to Rescue Neurons in ALSThe chief medical officer of QurAlis discussed the antisense oligonucleotide therapy QRL-201.
Latest:
Next Steps for Car T-Cell Therapy in Multiple Myeloma: Faith E. Davies, MDThe director of the Clinical Myeloma Program at NYU Langone Health’s Perlmutter Cancer Center discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
Latest:
Caspian Oliai, MD, MS, on Making Allo-Transplant Safer for Older PatientsThe medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center discussed results from a phase 1b trial for allo-HCT alternative Orca-T that he presented at Tandem’s 2024 conference.
Latest:
Clinical Implications of CAR T-Cell Therapy in R/R Myeloma: Frits van Rhee, MD, PhDThe professor and director of the Myeloma Center at the University of Arkansas for Medical Sciences discussed the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.
Latest:
Gene Therapy: The Future of Rare Disease TreatmentExperts shared opinions about the future of gene therapy in sickle cell and other rare diseases.
